Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin ®) in Patients with Non-squamous Non-small Cell Lung Cancer

ConclusionsPopPK analysis revealed no significant differences between pharmacokinetics of MYL-1402O and Avastin® in patients with nsNSCLC. The developed PopPK model was considered robust, as it adequately described bevacizumab pharmacokinetics in healthy participants and nsNSCLC patients.

http://link.springer.com/10.1007/s13318-023-00855-3

Source: European Journal of Drug Metabolism and Pharmacokinetics - October 4, 2023 Category: Drugs & Pharmacology Source Type: research